Final Overall Survival Analysis of the LATITUDE Trial in Newly Diagnosed, High-Risk, Metastatic, Castration-Sensitive Prostate Cancer

Final Overall Survival Analysis of the LATITUDE Trial in Newly Diagnosed, High-Risk, Metastatic, Castration-Sensitive Prostate Cancer – The ASCO POST (free)

Original Article: Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial – The Lancet Oncology (link to abstract – 4 for full-text)